Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
May 13 2020 - 10:00AM
Business Wire
Pfizer Inc. (NYSE: PFE) announced today that it will be holding
its rescheduled Investor Day on Monday, September 14, 2020 at 9:00
a.m. EDT. Pfizer postponed its Investor Day, originally scheduled
for March 31, 2020, due to health and safety concerns around the
COVID-19 pandemic.
Information on registering for in-person or virtual attendance
will be provided at a later date. A live webcast, including audio,
video and presentation slides, will be accessible on
www.pfizer.com/investors at the time of the meeting. Interested
parties unable to attend in-person or watch the live webcast will
be able to view and listen to an archived copy of the webcast,
which will be available on www.pfizer.com/investors following the
conclusion of the event.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, our
anticipated operating and financial performance, business plans and
prospects, expectations for our product pipeline, in-line products
and product candidates, including anticipated regulatory
submissions, data read-outs, study starts, approvals, revenue
contribution, growth, performance, timing of exclusivity and
potential benefits, strategic reviews, capital allocation
objectives, plans for and prospects of our acquisitions and other
business-development plans, benefits anticipated from the
reorganization of our commercial operations in 2019, plans for and
prospects of our acquisitions and other business development
activities, including our proposed transaction with Mylan N.V.
(Mylan) to combine Upjohn and Mylan to create a new global
pharmaceutical company, Viatris, our acquisition of Array BioPharma
Inc. and our transaction with GSK which combined our respective
consumer healthcare businesses into a new consumer healthcare joint
venture, our ability to successfully capitalize on growth
opportunities or prospects, manufacturing and product supply and
plans relating to share repurchases and dividends, among other
things, that are subject to substantial risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by such statements. A description of these
risks and uncertainties can be found in Pfizer’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2019 and in its
subsequent reports on Form 10-Q, including in the sections thereof
captioned “Risk Factors” and “Forward-Looking Information and
Factors That May Affect Future Results”, as well as in its
subsequent reports on Form 8-K, all of which are filed with the
U.S. Securities and Exchange Commission and available at
www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200513005424/en/
Media Relations:
Amy Rose +1 (646) 592-3157 Amy.Rose@Pfizer.com Investor Relations: Ryan Crowe +1 (212) 733-8160 Ryan.Crowe@Pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024